These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 30114438

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
    Feng F, Jiang Q, Cao S, Cao Y, Li R, Shen L, Zhu H, Wang T, Sun L, Liang E, Sun H, Chai Y, Li X, Liu G, Yang R, Yang Z, Yang Y, Xin S, Li BA.
    Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
    [Abstract] [Full Text] [Related]

  • 5. Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhu Q, Ren H, Li X, Qian B, Fan S, Hu F, Xu L, Zhai B.
    Aging (Albany NY); 2020 Nov 16; 12(22):22975-23003. PubMed ID: 33203790
    [Abstract] [Full Text] [Related]

  • 6. Phthalates promote the invasion of hepatocellular carcinoma cells by enhancing the interaction between Pregnane X receptor and E26 transformation specific sequence 1.
    Du Y, Shi X, Ma W, Wen P, Yu P, Wang X, Fang P, Chen A, Gao Z, Cui K.
    Pharmacol Res; 2021 Jul 16; 169():105648. PubMed ID: 33965509
    [Abstract] [Full Text] [Related]

  • 7. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
    Dong XF, Liu TQ, Zhi XT, Zou J, Zhong JT, Li T, Mo XL, Zhou W, Guo WW, Liu X, Chen YY, Li MY, Zhong XG, Han YM, Wang ZH, Dong ZR.
    Clin Cancer Res; 2018 Jul 01; 24(13):3204-3216. PubMed ID: 29514844
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, Lan PC, Yang MH, Chang TS, Huang YH.
    J Exp Clin Cancer Res; 2019 Nov 26; 38(1):474. PubMed ID: 31771617
    [Abstract] [Full Text] [Related]

  • 11. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar 26; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 12. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul 26; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 13. Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma.
    Vishnoi K, Ke R, Viswakarma N, Srivastava P, Kumar S, Das S, Singh SK, Principe DR, Rana A, Rana B.
    Cell Death Dis; 2022 Jul 04; 13(7):581. PubMed ID: 35789155
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways.
    Jiang W, Li G, Li W, Wang P, Xiu P, Jiang X, Liu B, Sun X, Jiang H.
    Sci Rep; 2018 Jun 26; 8(1):9706. PubMed ID: 29946188
    [Abstract] [Full Text] [Related]

  • 16. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H, Xu H, Ma F, Zhan M, Yang X, Hua S, Li W, Li Y, Lu L.
    Cell Death Dis; 2020 Apr 08; 11(4):225. PubMed ID: 32269215
    [Abstract] [Full Text] [Related]

  • 17. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
    Tan W, Luo X, Li W, Zhong J, Cao J, Zhu S, Chen X, Zhou R, Shang C, Chen Y.
    EBioMedicine; 2019 Feb 08; 40():446-456. PubMed ID: 30594557
    [Abstract] [Full Text] [Related]

  • 18. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
    Long Q, Zou X, Song Y, Duan Z, Liu L.
    Biochem Biophys Res Commun; 2019 Jun 04; 513(3):642-650. PubMed ID: 30981500
    [Abstract] [Full Text] [Related]

  • 19. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 20. GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
    Zhou Y, Zhao H, Ren R, Zhou M, Zhang J, Wu Z, Chen Y, Lei J, Chen Y, Yu Y, Li Y.
    Theranostics; 2024 Oct 06; 14(9):3470-3485. PubMed ID: 38948063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.